Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 11 | 2023 | 102 | 4.660 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 339 | 4.170 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2022 | 38 | 4.000 |
Why?
|
| Neoplasms | 8 | 2022 | 756 | 1.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 131 | 1.540 |
Why?
|
| Immunotherapy | 9 | 2022 | 134 | 1.180 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 128 | 1.080 |
Why?
|
| Melanoma | 2 | 2019 | 140 | 1.070 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2022 | 130 | 0.880 |
Why?
|
| Liver Neoplasms | 5 | 2022 | 164 | 0.850 |
Why?
|
| Myocarditis | 1 | 2022 | 16 | 0.810 |
Why?
|
| Interleukin-6 | 3 | 2023 | 190 | 0.770 |
Why?
|
| Humans | 35 | 2023 | 26856 | 0.710 |
Why?
|
| Retrospective Studies | 12 | 2022 | 2444 | 0.690 |
Why?
|
| Research Design | 1 | 2021 | 173 | 0.690 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 316 | 0.660 |
Why?
|
| Neutropenia | 1 | 2019 | 35 | 0.660 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 66 | 0.650 |
Why?
|
| Azetidines | 1 | 2019 | 6 | 0.650 |
Why?
|
| Exanthema | 1 | 2019 | 14 | 0.640 |
Why?
|
| Piperidines | 1 | 2019 | 42 | 0.620 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2017 | 1 | 0.600 |
Why?
|
| Aged | 13 | 2022 | 5169 | 0.590 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 143 | 0.590 |
Why?
|
| Bone Marrow Diseases | 1 | 2017 | 2 | 0.590 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2017 | 4 | 0.590 |
Why?
|
| Ehrlichiosis | 1 | 2017 | 5 | 0.580 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 8 | 0.580 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 12 | 0.570 |
Why?
|
| Biological Products | 1 | 2017 | 60 | 0.530 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 377 | 0.520 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2022 | 37 | 0.500 |
Why?
|
| Inflammation | 2 | 2022 | 598 | 0.470 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 1927 | 0.430 |
Why?
|
| Female | 14 | 2021 | 14462 | 0.400 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 144 | 0.370 |
Why?
|
| Male | 13 | 2022 | 12866 | 0.350 |
Why?
|
| Pneumonia | 2 | 2021 | 89 | 0.350 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 457 | 0.330 |
Why?
|
| Middle Aged | 9 | 2021 | 6825 | 0.320 |
Why?
|
| Colitis | 2 | 2019 | 53 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2022 | 2267 | 0.300 |
Why?
|
| Prognosis | 5 | 2022 | 758 | 0.300 |
Why?
|
| Skin | 2 | 2019 | 140 | 0.280 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 27 | 0.250 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 60 | 0.240 |
Why?
|
| Adenosine | 1 | 2023 | 33 | 0.220 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 93 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 106 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 74 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 3 | 0.210 |
Why?
|
| Up-Regulation | 1 | 2023 | 239 | 0.210 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 6 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 146 | 0.200 |
Why?
|
| Adult | 5 | 2021 | 7389 | 0.200 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 34 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2021 | 3 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 108 | 0.190 |
Why?
|
| Pyrimidinones | 1 | 2021 | 15 | 0.190 |
Why?
|
| Random Allocation | 1 | 2021 | 148 | 0.190 |
Why?
|
| Thyroiditis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2020 | 277 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 95 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2021 | 62 | 0.180 |
Why?
|
| Withholding Treatment | 1 | 2020 | 20 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 32 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 247 | 0.170 |
Why?
|
| Bone Marrow | 2 | 2017 | 76 | 0.170 |
Why?
|
| Radioimmunotherapy | 1 | 2019 | 1 | 0.170 |
Why?
|
| Biopsy | 2 | 2017 | 199 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2019 | 66 | 0.160 |
Why?
|
| United States | 2 | 2022 | 2035 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 39 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2021 | 860 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 184 | 0.160 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 5 | 0.160 |
Why?
|
| Survival Rate | 1 | 2020 | 407 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 151 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 152 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 144 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 10 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 26 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 981 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 2017 | 24 | 0.140 |
Why?
|
| HIV-1 | 1 | 2017 | 54 | 0.140 |
Why?
|
| Cytokines | 1 | 2019 | 437 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2017 | 252 | 0.140 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 1 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 98 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 21 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 162 | 0.130 |
Why?
|
| Disease Progression | 1 | 2017 | 450 | 0.130 |
Why?
|
| Biomarkers | 1 | 2019 | 731 | 0.130 |
Why?
|
| HIV Infections | 1 | 2017 | 146 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 206 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 505 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 820 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2022 | 96 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 218 | 0.090 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 54 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 48 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 93 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 10 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2021 | 14 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 67 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 118 | 0.050 |
Why?
|
| Patient Safety | 1 | 2021 | 36 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2021 | 67 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 128 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 245 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 123 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 140 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 274 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 12 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 586 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2022 | 511 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 1130 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2020 | 1219 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1564 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2016 | 8 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 72 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 16 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 2017 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 453 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 368 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2584 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 2960 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 395 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 1339 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 9954 | 0.020 |
Why?
|